Kura Oncology (KURA) EBITDA Margin (2025 - 2026)
Kura Oncology (KURA) reported EBITDA Margin of 409.18% for Q1 2026, down 360.0% year-over-year from 157.38% in Q1 2025, and up 12.31% quarter-over-quarter from 466.62% in Q4 2025.
Kura Oncology (KURA) EBITDA Margin (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has 2 years of EBITDA Margin data on file, last reported at 409.18% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 409.18%, down 360.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 413.08% (changed N/A YoY), and the FY2025 annual result was 412.56%, down 9345.0% from the prior year.
- EBITDA Margin grew to 409.18% in Q1 2026 per KURA's latest filing, from 466.62% in the prior quarter.
- Over five years, EBITDA Margin peaked at 356.19% in Q3 2025 and troughed at 466.62% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Kura Oncology | 883.44 Mn | 883.44 Mn | 18.00 Mn | -409.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -409.18% |
| Dec 31, 2025 | -466.62% |
| Sep 30, 2025 | -356.19% |
| Jun 30, 2025 | -434.23% |
| Mar 31, 2025 | -405.58% |